Drugs / Tegafur-Gimeracil-Oteracil
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07182565 | Nov 2025 → Aug 2029 expected | gastroesophageal junction adenocarcinoma | West China Hospital | Recruiting | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT07386704 | Dec 2025 → Dec 2026 expected | malignant pancreatic neoplasm | Peking University First Hospital | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT06255379 | May 2024 → Mar 2027 expected | colon carcinoma, metastasis from malignant tumor of colon, rectal carcinoma | Guangzhou University of Traditional Chinese Medicine | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05161572 | Sep 2021 → Sep 2022 | gastric neoplasm, gastroesophageal adenocarcinoma, gastroesophageal junction adenocarcinoma | Fudan University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT04377048 | Jul 2020 → Jul 2022 | pancreas disorder | National Taiwan University Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT03904225 | Dec 2018 → Dec 2022 | nasopharyngeal carcinoma | Zhejiang Cancer Hospital | Unknown | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06662877 | Nov 2024 → Sep 2029 expected | biliary tract cancer | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05813015 | Jan 2023 → Dec 2026 expected | chemotherapy-induced toxicity, gastric adenocarcinoma | Zhejiang University | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tegafur Gimeracil Oteracil | “oral administration of tegafur-gimeracil-oteracil (S-1) for 14 consecutive days followed by a 7-day rest period (21-day cycle)” NCT07182565 ↗7“Tegafur-gimeracil-oteracil (S-1): 80-120mg per day, taken twice a day, from day 1 to day 14, and from day 21 onwards.” NCT07386704 ↗ “Drug: Tegafur-Gimeracil-Oteracil” NCT05813015 ↗ |
| Known as | S-1 | “oral administration of tegafur-gimeracil-oteracil (S-1) for 14 consecutive days followed by a 7-day rest period (21-day cycle)” NCT07182565 ↗2“Tegafur-gimeracil-oteracil (S-1): 80-120mg per day, taken twice a day, from day 1 to day 14, and from day 21 onwards.” NCT07386704 ↗ “Tegafur Gimeracil Oteracil (S-1) 40-60mg,p.o,bid,d1-d14,Q3W” NCT06662877 ↗ |
| Route | Oral | “oral administration for 12 months” NCT03904225 ↗ |